109 related articles for article (PubMed ID: 6234517)
1. Effect of aliphatic monoamines on motor activity of mice: no direct interaction with dopaminergic D2 receptor.
Widy-Tyszkiewicz E; Członkowski A
Pol J Pharmacol Pharm; 1983; 35(6):467-72. PubMed ID: 6234517
[TBL] [Abstract][Full Text] [Related]
2. Effects of a fluorinated pyrimidinedione anti-cancer drug, 5-fluoro-1-(tetrahydro-2-furanyl)-2,4-pyrimidinedione (FT), and related compounds on nigro-striatal dopaminergic neurons in the central nervous system.
Toide K; Unemi N; Segawa T
Arch Int Pharmacodyn Ther; 1985 Mar; 274(1):111-24. PubMed ID: 3925907
[TBL] [Abstract][Full Text] [Related]
3. Central effects of CGP 37849 and CGP 39551, competitive NMDA receptor antagonists, in mice.
Maj J; Rogóz Z; Skuza G
Pol J Pharmacol; 1993; 45(4):349-60. PubMed ID: 7906989
[TBL] [Abstract][Full Text] [Related]
4. Sensitive periods for the effect of haloperidol on development of striatal dopamine receptors.
Rosengarten H; Friedman E; Friedhoff AJ
Birth Defects Orig Artic Ser; 1983; 19(4):511-3. PubMed ID: 6871420
[No Abstract] [Full Text] [Related]
5. The effect of dopamine receptor agonist treatment on haloperidol-induced supersensitivity in mice.
Fayle P; Jackson DM; Jenkins OF; Lafferty PA
Pharmacol Biochem Behav; 1985 Nov; 23(5):715-20. PubMed ID: 4080755
[TBL] [Abstract][Full Text] [Related]
6. The behavioral effects of the stereoisomers of 4-methylaminorex, a psychostimulant, in the rat.
Batsche K; Ashby CR; Lee C; Schwartz J; Wang RY
J Pharmacol Exp Ther; 1994 Jun; 269(3):1029-39. PubMed ID: 7912274
[TBL] [Abstract][Full Text] [Related]
7. Haloperidol-induced behavioral supersensitivity is increased by monosialoganglioside treatment in rats without affecting spiroperidol-binding.
Schröder U; Schröder H; Augustin W; Sabel BA
J Pharmacol Exp Ther; 1994 Dec; 271(3):1193-6. PubMed ID: 7996425
[TBL] [Abstract][Full Text] [Related]
8. Distinctions between ligand-binding sites for [3H]dopamine and D2 dopaminergic receptors characterized with [3H]spiroperidol.
Hancock AA; Marsh CL
Mol Pharmacol; 1984 Nov; 26(3):439-51. PubMed ID: 6238230
[TBL] [Abstract][Full Text] [Related]
9. Reserpine-induced up-regulation of dopamine D2 receptors in the rat striatum is enhanced by denervation but not by chronic receptor blockade.
Traub M; Reches A; Wagner HR; Fahn S
Neurosci Lett; 1986 Oct; 70(2):245-9. PubMed ID: 2946007
[TBL] [Abstract][Full Text] [Related]
10. Beta-phenylethylamine and locomotor activity in mice. Interaction with catecholaminergic neurones and receptors.
Jackson DM
Arzneimittelforschung; 1975 Apr; 25(4):622-6. PubMed ID: 168908
[TBL] [Abstract][Full Text] [Related]
11. Quantitative image analysis with densitometry for immunohistochemistry and autoradiography of receptor binding sites--methodological considerations.
Peretti-Renucci R; Feuerstein C; Manier M; Lorimier P; Savasta M; Thibault J; Mons N; Geffard M
J Neurosci Res; 1991 Apr; 28(4):583-600. PubMed ID: 1678436
[TBL] [Abstract][Full Text] [Related]
12. Factors contributing to the up regulation of dopaminergic receptors by chronic haloperidol.
Schweitzer JW; Schwartz R; Friedhoff AJ
Res Commun Chem Pathol Pharmacol; 1982 Oct; 38(1):21-30. PubMed ID: 7146618
[TBL] [Abstract][Full Text] [Related]
13. Further characterization of structural requirements for agonists at the striatal dopamine D2 receptor and a comparison with those at the striatal dopamine D1 receptor. Studies with a series of monohydroxyaminotetralins on acetylcholine release from rat striatum.
Seiler MP; Markstein R
Mol Pharmacol; 1984 Nov; 26(3):452-7. PubMed ID: 6238231
[TBL] [Abstract][Full Text] [Related]
14. Interactions of neurotensin with brain dopamine systems: biochemical and behavioral studies.
Nemeroff CB; Luttinger D; Hernandez DE; Mailman RB; Mason GA; Davis SD; Widerlöv E; Frye GD; Kilts CA; Beaumont K; Breese GR; Prange AJ
J Pharmacol Exp Ther; 1983 May; 225(2):337-45. PubMed ID: 6682440
[TBL] [Abstract][Full Text] [Related]
15. Disulfiram and diethyldithiocarbamate intoxication affects the storage and release of striatal dopamine.
Vaccari A; Saba PL; Ruiu S; Collu M; Devoto P
Toxicol Appl Pharmacol; 1996 Jul; 139(1):102-8. PubMed ID: 8685891
[TBL] [Abstract][Full Text] [Related]
16. The effect of intraventricular dopamine on the spontaneous locomotor activity of rats pretreated with nialamide, reserpine, or alpha-methyl-p-tyrosine.
Malec D; Kleinrok Z
Pol J Pharmacol Pharm; 1973; 25(4):357-66. PubMed ID: 4774244
[No Abstract] [Full Text] [Related]
17. [SDZ HDC 912 as a dopamine receptor partial agonist: the effect on spontaneous locomotor activity in mice].
Kameda H; Watanabe H
Yakubutsu Seishin Kodo; 1991 Oct; 11(5):327-30. PubMed ID: 1688174
[TBL] [Abstract][Full Text] [Related]
18. [Effect of repeated haloperidol and apomorphine administration on the development of tolerance for catalepsy and dopamine receptor hypersensitivity in mice].
Zharkovskiĭ AM; Matvienko OA; Nurk AM
Biull Eksp Biol Med; 1984 Oct; 98(10):444-6. PubMed ID: 6541951
[TBL] [Abstract][Full Text] [Related]
19. Effects of a partial D2-like receptor agonist on striatal dopamine autoreceptor functioning in preweanling rats.
Yoshida ST; Baella SA; Stuebner NM; Crawford CA; McDougall SA
Brain Res; 2006 Feb; 1073-1074():269-75. PubMed ID: 16427034
[TBL] [Abstract][Full Text] [Related]
20. Long-term haloperidol treatment (but not risperidone) enhances addiction-related behaviors in mice: role of dopamine D2 receptors.
Carvalho RC; Fukushiro DF; Helfer DC; Callegaro-Filho D; Trombin TF; Zanlorenci LH; Sanday L; Silva RH; Frussa-Filho R
Addict Biol; 2009 Jul; 14(3):283-93. PubMed ID: 19298320
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
